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Abstract 
The incidence of esophageal adenocarcinoma (EAC) has increased in many Western countries, 
and is higher in men than women. Some risk factors for EAC have been identified—mainly 
gastroesophageal reflux disease (GERD), Barrett’s esophagus, obesity, and tobacco smoking. It 
is not clear whether interventions to address these factors can reduce risk of EAC, although some 
evidence exists for smoking cessation. Although consumption of alcohol is not associated with 
EAC risk, other exposures, such as physical activity, nutrition, and medication use, require 
further study. Genetic variants have been associated with risk for EAC, but their overall 
contribution is low. Studies are needed to investigate associations between risk factors and the 
molecular subtypes of EAC. The prognosis for patients with EAC has slightly improved, but 
remains poor—screening and surveillance trials of high-risk individuals are needed.  
 
Keywords: Epidemiology; Lifestyle; Genetic risk; Esophageal cancer  
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Esophageal adenocarcinoma (EAC) is characterized by several epidemiologic features. Over the 
past 30 years, there has been a rapid increase in the incidence of EAC in many Western countries, 
including Europe, North America, and Australia—EAC is the most rapidly increasing form of 
cancer in some populations.1,2 The male predominance in incidence is stronger than that of any 
other non–sex-specific cancer in several populations.2,3 Although strong risk factors for EAC 
have been identified, mainly gastroesophageal reflux disease (GERD) and obesity, we are in 
need of evidence-based preventive strategies.2,4 The prognosis for patients diagnosed with EAC 
has slightly improved during the last few decades, but it is still worse than that of most other 
cancer types; only 20% of patients in Western populations survive for 5 years.5–7 This review 
summarizes the current knowledge in the epidemiology and prevention of EAC, and highlights 
unresolved research questions regarding these topics. 
 
Incidence 
EAC is the main histological type of esophageal cancer in the West. In 2012, an estimated 
52,000 individuals (41,000 men and 11,000 women) developed EAC worldwide, resulting in a 
global incidence rate of 0.7 per 100,000 person-years (1.1 in men and 0.3 in women); most 
patients (53%) were from Europe, Northern America, or Oceania.8 The incidence rate of EAC 
has surpassed that of esophageal squamous cell carcinoma in a number of Western countries, 
including the United Kingdom (UK), the Netherlands, Ireland, New Zealand, the United States 
(US), Australia, Denmark, Canada, and Sweden.8–11  
 
Geographic and racial/ethnic variations 
The incidence rate of EAC varies greatly across geographic regions. The age-standardized 
incidence rate of EAC in 2012 was highest in Northern and Western Europe, Northern America, 
and Oceania, but was as low as less than 1 per 100,000 person-years in both sexes in the 
remaining parts of the world.8 At the individual country level, the highest rates per 100,000 
person-years have been observed in the UK (7.2 in men and 2.5 in women), the Netherlands (7.1 
in men and 2.8 in women), and Ireland (3.9 in men and 2.7 in women).8 In the US, the incidence 
rates are highest in non-Hispanic whites, followed by Hispanic whites, American Indian/Alaska 
Native, blacks, and lowest in Asian/Pacific islanders.12,13 
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Time trends  
Figure 1 shows the incidence trends of EAC since the 1970s in White Americans and in Sweden. 
The increase in the incidence of EAC seems to have started in the 1970s in Europe, North 
America, and Australia.1 Some reports have suggested that EAC incidence might have reached a 
plateau in recent years,14,15 whereas other studies found a continued increase.1,10 A 
comprehensive assessment based on data from 8 Western countries, including incidence rates 
through the year 2009, indicated a continuing increase at seemingly unchanged rates; these 
ranged from an average 3.5% per year in Scotland to 8.1% per year in Hawaii.1 The most recent 
update of EAC incidence, with data from Sweden through the year 2014, reported a continued 
increase, although the increase seemed to have slowed down to 2.6% per year in men from year 
2000 onwards.16 A simulation model of the EAC incidence in the US estimates that incidence 
will continue to increase until 2013, but plateau for recent birth cohorts in men.17 The incidence 
of EAC has remained much lower in Asian populations, although a trend towards a increase has 
been noted in a few Asian countries, including Singapore and Israel.18–20 Time trends in EAC 
incidence should be monitored in different populations worldwide. 
 
Age and sex distribution 
EAC incidence increases with age,10,21 similar to the age-specific incidence patterns of most 
epithelial cancers. EAC is characterized by a striking male predominance in incidence—the 
excess risk in men is greatest in the US, where the male:female incidence ratio of as high as 
9:1.3,8,22 A recent assessment of the sex-specific incidence rates in continents reported that ratios 
of incidence in men:women are also high in Northern America (7.6), Oceania (6.2), and Europe 
(6.0); ratios are lower in Asia (4.4), Latin America and the Caribbean (3.9), and Africa (1.0). The 
sex ratio has remained relatively stable over time in most populations, but has steadily increased 
in the UK and the Netherlands.22  
 
Genetic Factors 
Technical innovations and increasing affordability of large-scale genetic studies have led to the 
identification of germline (inherited) variants that affect risk for EAC. Somatic variants (not 
inherited) that affect risk of EAC are covered in a separate article in this issue, by Graham et al.23  
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Approximately 7% of cases of Barrett’s esophagus (BE) or EAC occur within families.24–26 
Familial cases develop at an earlier age than sporadic EACs.27,28 Other risk factors for EAC, such 
as regurgitation, smoking and obesity, are less prevalent among individuals with familial BE or 
EAC.27 However, these findings might have been affected by participant and reporting biases, 
due to comparisons with family controls.  
 
In 2016, researchers identified a germline mutation associated with a subset of EAC cases. A 
whole-exome sequencing study of a multi-generational family, in which 14 members were 
affected by BE or EAC, identified a variant in the V-set and immunoglobulin domain containing 
10 like gene (VSIG10L), encoding S631G, as a possible cause of familial EAC.29 The 
identification of this mutation provides opportunities for screening and surveillance of 
individuals with family members affected by BE or EA, depending on its prevalence. In future, 
the mutation could be incorporated into a risk prediction model, such as the BE Translational 
Research Network model, which combines family history and clinical risk factors to identify 
individuals at high risk for BE.30  
 
Candidate gene studies 
Many candidate genes have been evaluated in relation to EAC and BE risk. A systematic review 
identified 31 studies reporting on 187 different candidate germline mutations and risk of these 
lesions.31 Few had been investigated in more than 1 study, many had methodologic flaws, so the 
ability to conduct meta-analyses has been limited. A variant in only the glutathione S-transferase 
pi 1 gene (GSTP1) (rs1695) was consistently associated with BE, with the ‘G’ allele increasing 
risk of BE by 50%.31 Variants in genes encoding several growth factors and interleukins, and in 
caudal type homeobox 1 (CDX1), were also associated with risk and encoded proteins with 
plausible involvement in carcinogenesis.31 Germline variants in genes that regulate 
inflammation,32 androgen signaling,33 and cancer-related processes34–36 (such as apoptosis and 
angiogenesis, or in oncogenes or tumor suppressor genes) have also been investigated for their 
association with risk of EAC.  
 
Genome-wide association studies (GWAS) 
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GWAS for BE and EAC risk have been reported from various consortia since 2012.37–39 These 
have identified a number of single nucleotide polymorphisms (SNPs) associated with risk 
(associated with loci at or close to the MHC region, FOXF1, GDF7, TBX5, FOXP1, CRTC1, 
BARX1 and ALDHIA2 genes).37–39 Many of these associations have been replicated in subsequent 
studies.40,41 One of the largest initiatives has pooled analyses of all GWAS studies published 
until February 2016, comprising 6167 cases of BE, 4112 cases of EAC, and 17,159 controls.42 
These confirmed associations for all 8 previously identified SNPs, along with 8 new risk loci; 2 
of these are linked to genes that regulate body fat.42 One variant (rs9823696, near ABCC5 and 
HTR3C) was associated with EAC risk independently of BE, so it might be used to identify 
patients with BE at high risk for EAC.42  
 
Mendelian randomization studies are useful for studying genetic variants as instrumental 
variables, or proxies, for modifiable factors. They overcome issues of confounding, because the 
inheritance of alleles from each parent should occur randomly. This approach has been used to 
confirm associations between body composition measures and EAC risk (for example 30%–43% 
reduced risks of EAC per 10 cm increase in height, and 16% increased EAC risk per 1 kg/m2 
increment in body mass index (BMI)).43,44 
 
Genetic factors associated with EAC and clinical utility 
Up to one third of EAC may be hereditary and attributed to a combination of germline 
mutations,45 although single mutations are associated with only a 20% increase in risk of EAC, at 
most.26 However, the sharp increase in EAC incidence in many countries cannot be accounted 
for by changes in the population’s genetic make-up over a timeframe of only 50 years. Genetic 
predisposition might account for some of the variation in geographical incidence of EAC. For 
example, variants in the cystic fibrosis transmembrane conductance regulator gene (CFTR) 
associated with EAC in a GWAS are also associated with cystic fibrosis, which can be associated 
with reflux symptoms.42 Both diseases have a high incidence in the UK and Ireland;8,46 it is 
possible this variant is more common in people of Celtic descent.  
 
The clinical utility of understanding genetic variants associated with EAC risk is perhaps limited, 
given the common prevalence and relatively low risk of EAC associated with many of the SNP 
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variants identified.26,47 However, the contribution of genetic studies to the enhanced biological 
understanding of susceptibility to EAC should not be underestimated. It is important to study 
interactions between genetic and environmental factors that affect risk for EAC, as these might 
increase our understanding of temporal trends in EAC incidence. For example variants in FOXP1 
modify the association between GERD and risk of BE.48 However, such studies would require 
large samples sizes that are pragmatically difficult to achieve.  
 
Non-genetic Risk Factors 
Gastroesophageal reflux disease 
GERD was first established as a risk factor for EAC in the late 1990s,49,50 and confirmed in 
population-based studies.51–54 A pooled analysis of 5 population-based case–control studies 
indicated a strong association between heartburn or regurgitation, the 2 most common GERD 
symptoms, and EAC risk (see Figure 2).51 The risk of EAC in individuals with heartburn for at 
least 30 years was 6.2-fold higher than in individuals without heartburn.51 A recent analysis of 
same 5 studies, along with 3 additional studies, showed that the association was stronger in 
adults younger than 50 years compared with older age groups.55  
 
BE 
BE, the precursor to EAC, is characterized by metaplastic changes in the esophageal lining, from 
normal squamous to a specialized columnar epithelium, in patients with chronic GERD. The 
tumor development process involves consecutive changes, from erosive esophagitis to non-
dysplastic BE, low-grade dysplasia, high-grade dysplasia, adenocarcinoma in situ, and finally 
invasive adenocarcinoma.56 Individuals with BE and long-term GERD and additional risk factors 
should be screened by upper endoscopy for dysplastic BE or early-stage, curable EAC.57,58 
However, EACs are missed in a large proportion of patients with BE, in spite of the screening 
strategy, because approximately 40% do not report GERD symptoms.59  
 
Temporal trends of GERD and BE 
The temporal trends of GERD are rarely assessed in longitudinal studies, although systematic 
reviews comparing GERD prevalence reported by population-based studies in different calendar 
periods have suggested an increase in GERD prevalence since the mid-1990s, particularly in 
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North America and East Asia.60,61 A population-based cohort study in Norway, of 29,610 
individuals followed up for an average of 11 years, found a 47% increase of at least weekly 
reflux symptoms from the period 1995–1997 to the period 2006–2009.62 It is likely that the 
increasing prevalence of GERD contributed the increasing incidence of EAC—particularly for 
the increase in more recent years. An increasing incidence of BE, particularly in younger men, 
was reported from 2 population-based European studies.63,64  
 
Anti-reflux therapies 
The cancer protective potential of anti-reflux therapies, such as acid-suppressing medications, 
particularly proton-pump inhibitors (PPIs), and anti-reflux surgery with fundoplication, has been 
evaluated in observational studies that produced inconsistent results.54,65–69 A meta-analysis of 5 
cohort studies and 2 case-control studies associated a 70% decrease in risk of EAC or high-grade 
dysplasia with PPI use in patients with BE (adjusted odds ratio [aOR], 0.29).68 However, a more 
recent meta-analysis of these 7 studies plus 2 additional population-based case–control studies 
found that the association was no longer statistically significant (unadjusted OR, 0.43); no 
association was found in an analysis restricted to 5 studies with higher scientific quality and 
adjustment for confounders (aOR, 0.95).69 A recent systematic review and meta-analysis of 12 
studies indicated that anti-reflux surgery might prevent EAC better than anti-reflux medication in 
patients with GERD (incidence rate ratio, 0.76), although it was not possible to make 
conclusions from this study, due to the limited sample size and possible bias and confounding in 
existing studies.67 The ability of anti-reflux therapies to prevent EAC remains requires evaluation 
in large-scale studies with long follow-up periods and control for confounding factors. 
 
Obesity 
Increasing BMI has been consistently associated with increasing risk of EAC, in a seemingly 
linear exposure–response pattern.52,70–72 Interestingly, the association between childhood or 
adolescent BMI and EAC risk seems to be stronger than that of adulthood BMI.73 The increasing 
prevalence of obesity in Western populations could partially account for the increasing incidence 
of EAC. However, the increasing incidence of EAC seems to have started before the start of the 
obesity epidemic.74–76 A quantitative assessment has shown that the increase in obesity 
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prevalence may account for only a limited part (6.5%) of the increase in EAC incidence in the 
US.74 
 
There are several potential mechanisms behind the association between obesity and EAC risk. A 
mechanical contribution might be gastric compression due to extensive intra-abdominal adipose 
tissue causing increased intra-gastric pressure and disruption of the gastroesophageal junction 
and the lower esophageal sphincter, which could lead to GERD.77–81 Obesity is a systemic 
disease that may increase EAC risk through inflammatory and metabolic alterations.81 Studies 
have indicated associations between serum leptin and insulin levels, as well as metabolic 
syndrome components, and an altered risk of BE.82–85  
 
A prospective cohort study of 392 patients with BE reported associations between increased 
levels of leptin and insulin and EAC risk, and an inverse association between high molecular-
weight adiponectin and EAC.86 A large prospective cohort study of 578,700 participants (Me-
Can) associated an increased risk of EAC with the metabolic syndrome (hazard ratio, 1.56 per 
unit increase of the composite z-score).87 One case–controls study associated the metabolic 
syndrome with EAC,88 whereas 2 other case–control studies did not.89,90 Metabolic profiling 
studies using high-performance liquid chromatography–mass spectrometry or nuclear magnetic 
resonance analysis identified some metabolic markers in serum that might differentiate patients 
with EAC from healthy individuals or patients with BE.91,92 These findings require validation in 
independent populations. 
 
Abdominal adiposity (typical male obesity) is associated with increased risk of EAC; this 
association seems to remain after adjustment for BMI.93,94 On the other hand, the association 
between BMI and EAC risk did not remain after adjustment for abdominal obesity.93 A meta-
analysis observed increased risk of BE associated with abdominal adiposity based on 11 studies, 
using patients with GERD as controls or adjusting for GERD symptoms, reported a reflux-
independent effect of abdominal adiposity on development of esophageal metaplasia.94 A 
prospective cohort study of 391,456 participants found an inverse association between gluteo-
femoral adiposity (typical female obesity), measured by hip circumference. The adjusted hazard 
ratio of EAC was 0.35 when the highest vs the lowest quintile were compared, after controlling 
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for waist circumference.95 These findings indicate a role for fat distribution in the male 
predominance in EAC. However, the male predominance seems to persist at a similar level even 
in lean individuals compared with overweight individuals.96 
 
Weight loss 
Weight loss might reduce risk of EAC development, although this has been difficult to 
investigate. To study this effect, researchers would have to assess effects of exposure to 
substantial and consistent voluntary weight loss. It might be possible to study patients who have 
undergone obesity surgeries, but this would require large-scale investigations with long follow-
up periods. A nationwide Swedish population-based cohort study of 34,437 patients who had 
undergone obesity surgery identified only 8 patients with EAC during a median of 3.7 years of 
follow up; it found no clear difference in EAC between individuals who underwent obesity 
surgery and 123,695 obese individuals who did not receive surgery (hazard ratio, 0.9).97 It is 
therefore unclear whether weight loss is associated with a reduced risk of EAC. 
 
Microbes 
Infection with the gastric bacterium Helicobacter pylori has been associated with a decreased 
risk of EAC. Meta-analyses of observational studies have reported a 40%–60% reduced risk of 
EAC associated with H pylori infection.98–101 The prevalence of H pylori infection has decreased 
in Western populations since the middle of the 20th century, which was earlier than the start of 
the increasing incidence of EAC. So, the decreasing prevalence of H pylori infection may have 
contributed to the increasing EAC incidence in Western populations.76,102,103  
 
A possible mechanism of the inverse association between H pylori infection and EAC risk could 
include reduced volume and acidity of gastric juice, due to atrophic gastritis following H pylori 
infection, which in turn could counteract GERD and thereby reduce the risk of EAC.104,105 
However, 2 meta-analyses found no increased risk of GERD following H pylori 
eradication,106,107 although the association between H pylori eradication and EAC remains to be 
examined in epidemiological studies.4,108  
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There have been few studies of the roles of bacteria other than H pylori in development of EAC. 
In a cultural analysis comparing esophageal biopsy specimens from 30 patients with EAC and 39 
controls, more bacterial species were identified in the EAC samples (73 species from 23 genera) 
than in controls (56 species from 19 genera).109 Evidence does not support an etiological role of 
infection with human papilloma virus in EAC.110–112  
 
The widespread introduction of antibiotics in the 1940s and the rapid increase in their use might 
have altered gastrointestinal microbiomes worldwide. Changes in species diversity or abundance 
of the esophageal microbiome might have contributed to the increasing incidence of EAC.76,113 
However, it is not clear how the intestinal microbiome affects risk of EAC—further studies are 
needed. Next-generation sequencing technologies have enabled characterization of the gut 
microbiome with high resolution, with 16S ribosomal RNA gene amplicons and shotgun 
metagenomics approaches.114 These techniques will advance studies of the gastrointestinal 
microbiome on EAC development. 
 
Tobacco smoking  
Tobacco smoking is a well-established and moderately strong risk factor for EAC in men and 
women, with ever smoking conferring an approximately doubled risk of EAC compared with 
never smoking (OR, 1.96).115 Pooled analysis of 10 case–control and 2 cohort studies within the 
International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) consortium 
confirmed a dose-response association between pack-years of tobacco smoking and EAC risk, 
rising to a 2.7-fold increased risk for individuals who had 45 or more pack-years of smoking 
history.115 Further, the Northern Ireland Barrett’s register reported an approximate 2-fold 
increased risk of progression from BE to EAC associated with tobacco smoking,116 a finding 
confirmed in subsequent smaller cohorts.117,118 Overall, it is plausible that tobacco smoking 
contributes to EAC development, given that tobacco is a carcinogen that causes DNA damage in 
Barrett’s epithelium.119 A recent US study of 81 samples associated tobacco smoking with DNA 
hypermethylation in esophageal tissues.120  
 
Importantly from a public health perspective, smoking cessation appears to reduce this risk of 
EAC; individuals who have stopped smoking for 10 years or more have an approximate 30% 
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reduced risk of EAC compared with current smokers.115 However, a recent meta-analysis of 23 
studies found only a small difference in the risk of EAC in comparing former and current 
smokers, and risk of EAC was reduced only among those who had stopped smoking for more 
than 20 years (risk ratio, 0.71).121 The risk of EAC in former smokers does not appear to return 
to the level observed in never-smokers,115,121 so primary prevention of smoking uptake in the 
population, particularly among children, should remain a priority.  
 
Health service studies are needed to evaluate partnerships between gastroenterology and 
smoking cessation clinics within hospitals, as are targeted smoking interventions for patients 
with BE or reflux. Given that smoking relaxes the lower esophageal sphincter, thereby 
potentially increasing acid reflux exposure, studies evaluating different smoking cessation 
modalities122 in these patients are warranted for maximal risk reduction.  
 
Alcohol consumption 
Although alcohol is a recognised risk factor for the development of many cancers,123–125 this 
association does not apply to EAC etiology. Pooled analysis from the International BEACON 
consortium confirmed no association between alcohol intake and an increased risk of EAC, even 
in individuals consuming the highest levels of alcohol (7 or more drinks per day compared with 
non-drinkers; OR, 0.97).126 The same pooled analysis, of 11 studies worldwide, found that 
moderate consumption of alcohol, and particularly wine, reduced EAC risk (0.5 to fewer than 1 
drink per day compared with non-drinkers; OR, 0.63).126  
 
Similar results have been observed in analyses of alcohol and BE risk from 5 population-based 
case–control studies within the same consortium.127 Further cohort studies have also reported no 
association between alcohol and the risk of progression from BE to EAC.116,128,129 These 
consistent findings contrast the strong, direct association between alcohol intake and esophageal 
squamous cell carcinoma risk.125,126 However, a 20% increase in risk of EAC was observed in 
individuals with alcohol-use disorders in a Swedish registry cohort study,130 so these largely null 
associations for EAC may not apply to individuals who chronically abuse alcohol. Due to coding 
as alcohol misuse, rather than an estimate of alcohol consumption, this study may be limited in 
its ability to adjust for known confounders.  
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It is unclear why alcohol is a carcinogen in other tissues, it does not contribute to development of 
EAC. Methodological biases in study designs are unlikely to explain this inconsistency, because 
these are not unique to epidemiological studies of EA. It is possible that individuals with GERD 
may alter (likely reduce) their alcohol consumption. The association between alcohol use and 
reduced risk of EAC is limited to individuals without symptoms of acid reflux.131 Others have 
attributed the protective effects of alcohol on EAC risk to changes in insulin resistance, lipid 
metabolism, or the anti-oxidants present in some alcoholic drinks.126 Further studies are required. 
  
Dietary factors 
Nutritional epidemiology is a particularly challenging field. It is a challenge to assess 
associations between disease outcomes and foods, nutrients, or composite dietary patterns or 
nutritional indices. The most comprehensive global report of diet, nutrition, and esophageal 
cancer, published in 2016, only considers evidence from cohort studies.125 In this report, no 
dietary aspects were judged to have strong evidence of an association with EAC risk, whereas 
only vegetable intake had limited suggestive evidence for a relation to a reduced risk of EAC.125  
 
Because EAC is relatively rare, most studies of diet, nutrition, and EAC risk are of case–control 
design. Such studies are prone to recall and socially desirable respondent biases, which can cause 
measurement errors, or issues of reverse causation when they evaluate biomarkers of nutritional 
status. Nevertheless, they provide useful insights in the absence of cohort study evidence. A 
meta-analysis of 8 case-control studies found no protective effect of dietary fiber on EAC risk; 
individuals consuming the highest compared with the lowest intakes of dietary fiber had 34% 
reduced odds of EAC (pooled OR, 0.66).132  
 
Evaluating the strength and consistency of evidence for the spectrum of foods, nutrients, and 
related biomarkers across reflux esophagitis, BE and EAC risk within the same population can 
somewhat help to overcome some limitations of the case–control design. This was the premise 
for a population-based study in Ireland (see Table 2).133–141 Intake of vitamin C, magnesium, 
folate, vitamin B6, and non-heme iron were associated with reduced risks of esophagitis, BE, and 
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EAC. The findings were supported by the inverse associations between BE, EAC and intake of 
fruit and vegetables, toenail iron, and ferritin levels in this population.   
 
Intake of dietary fat was consistently associated with increased risks of esophagitis, BE, and 
EAC. In contrast, several associations were made between only diet or nutritional exposures and 
EAC risk, indicating recall bias. Dietary fat was also associated with early stages of EAC 
development, in the inflammation–metaplasia–adenocarcinoma pathway. Overall, improvements 
in dietary assessment methods in population studies and large consortiums are needed to help 
strengthen the evidence for the associations between diet, nutrition, and EAC risk.  
 
Physical activity and sedentary behavior 
The 2016 World Cancer Research Fund/American Institute for Cancer Research continuous 
update project report on diet, nutrition, physical activity and esophageal cancer wrote that there 
is only “limited suggestive evidence” that physical activity reduces risk of EAC.125 This was 
despite findings from 2  meta-analyses (published in 2014) that risk for EAC was reduced by 
21%–32% in the most active vs the least active individuals.142,143 However, these pooled risk 
estimates were largely derived from case–control study estimates, which might be influenced by 
recall bias, whereas the associations observed in cohort studies were non-significant.144,145  
 
The Physical Activity Collaboration of the National Cancer Institute’s Cohort Consortium 
reported an association between self-reported physical activity and cancer risk in more than 1.44 
million adults.146 In their pooled analysis, high levels of physical activity associated with a 
reduced risk of EAC—more so than for any other cancer site (summary hazard ratio, 0.58, 
comprising 899 EAC cases from 5 studies). This inverse association remained after adjustment 
for BMI. However, in a stratified analysis, the protective effect was strongest for overweight and 
obese individuals, rather than healthy-weight individuals.146  
 
There is increasing recognition that sedentary behavior is distinct from physical activity level, 
and has adverse effects on health. There have been only a few studies of the effects of sedentary 
behavior and esophageal cancer risk—most reported no significant association.144,147,148 However, 
these were limited by inability to distinguish adenocarcinoma and squamous cell carcinoma 
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subtypes147,148 and small numbers of EAC cases.144 In contrast, a National Institutes of Health–
American Association of Retired Persons study reported a decreased risk of EAC in individuals 
who spent up to 6 hrs/day watching television (compared with less than 1 hr/day, adjusted hazard 
ratio, 0.57).149   
 
Overall, studies of physical activity, sedentary behavior and EAC risk to date have been 
hampered by lack of objective assessments of physical activity (such as accelerometers), and 
lack of understanding of the biological mechanisms involved. To our knowledge, only 1 trial has 
investigated exercise as a means for EAC prevention.150 In this Australian feasibility trial, 33 
men with BE underwent a 24-week moderate activity intervention. Results demonstrated a 
significant reduction in waist circumference, but not BMI or other obesity-related biomarkers 
investigated, although being a feasibility trial this was not powered to detect significant 
changes.150 This trial was hampered by difficulties in recruitment and the authors suggest a 
combined dietary and activity intervention may be more successful.150 Nevertheless, this study 
represents an important first step in the progression from observational epidemiology to lifestyle 
interventions in EAC risk reduction.  
 
Hormone and reproductive factors 
The strong male predominance in EAC led to investigations of whether sex hormones might be 
involved in the etiology of EAC. For example, estrogens might protect against esophageal cancer, 
or androgens might promote its development.3 A meta-analysis of 5 observational studies found 
a reduced risk of EAC in post-menopausal women who use menopause hormone therapy 
compared with non-users (pooled OR, 0.75), and a borderline significant decreased in risk 
associated with use of oral contraceptives (OR, 0.76).151 A Swedish cohort study confirmed the 
inverse association between menopause hormone therapy and EAC risk (OR, 0.62); the risk 
reduction was more pronounced in users less than 60 yrs old (OR, 0.20).152 However, 
confounding by indication might be a threat to the validity of these pharmaco-epidemiologic 
studies.  
 
The statistical power in previous epidemiological studies examining associations between 
reproductive factors and EAC risk was limited by the low incidence of EAC in women. 
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Interestingly, a pooled analysis of 3 population-based case–control studies revealed a decreased 
EAC risk associated with increasing duration of breastfeeding (OR, 0.42 for more than 12 
months).153  Continued research efforts are required to establish a role of sex hormone exposures 
in the etiology of EAC and to determine mechanisms.3  
 
Medications 
There are strong inverse associations between use of non-steroidal anti-inflammatory drugs 
(NSAIDs) and statins and the risk of EAC. A pooled analysis of 6 population-based 
observational studies associated NSAIDs use with a 32% reduced risk of EAC (OR, 0.68).154 A 
pooled analysis of 8 randomized clinical trials, in which EAC was not a primary endpoint of 
interest, comprising 25,570 patients, found a strongly reduced 20-year risk of death from EAC in 
daily aspirin users compared with non-users (hazard ratio, 0.36).155 However, the use of NSAIDs 
to prevent EAC development requires careful consideration of the absolute risk of EAC in 
individual patients and negative effects of these medications.4  
 
A meta-analysis of 3 cohort studies and 2 case–control studies associated use of statins with a 41% 
reduced risk of EAC in patients with BE (OR, 0.59).156 A recent case–control study nested in a 
cohort of patients with BE associated statistically non-significant reduction in EAC risk with 
statin use during over 3 years (OR, 0.5).66 The potential preventive effect of statins on EAC 
development should be confirmed in large randomized controlled trials. 
 
Observational studies have revealed an increased risk of EAC associated long-term use of drugs 
that relax the lower esophageal sphincter—particularly anticholinergics, which might be 
explained by a decreased pressure of the lower esophageal sphincter contributing to long-
standing gastroesophageal reflux.157–160  
 
Due to its estrogenic properties, digitalis medication has been proposed to influence the risk of 
sex hormone related cancers. A recent Swedish population-based cohort study of 156,385 
digitalis users and a comparison group of 551,993 users of organic nitrates associated digitalis 
use for at least 2 years with reduced risk of EAC (hazard ratio 0.48). The anti-cancer properties 
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of digitalis are being investigated in early-phase clinical trials of patients with cancer.161,162 
However, these trials might not be powered enough to assess EAC risk.  
 
In summary, although some medications appear to reduce risk of EAC, there is insufficient 
evidence for their use in EAC prevention. If protective effects of these drugs are confirmed in 
large controlled trials with sufficient length of follow up, it might become appropriate to 
introduce chemoprevention to individuals with high absolute risk of EAC, such as older men 
with obesity and GERD or individuals with BE, after balancing potential comorbidities in each 
patient.4 
 
Prognosis 
Generally, the overall prognosis in EAC is poor. This is mainly due to the late presentation of 
symptoms and the aggressiveness of this tumor. Most patients present with distant disease or a 
primary tumor with overgrowth of adjacent organs, making them incurable.163 There are few data 
on patient prognoses from many countries, but patients with esophageal have poor prognoses in 
most parts of the world, indicated by similar global rates of incidence and mortality.164 However, 
population-based studies have shown increases in 5-year survival, from less than 5% in the 
1960s to about 20% from year 2000 and later in some European countries, the US, and China.5–
7,165
 The most important prognostic factor is tumor stage, supporting the critical role for early 
detection for EAC. Rates of survival of patients with EAC vary with tumor stage in Northern 
Ireland (see Figure 3). Five-year survival rates decrease from 80.5% in the small proportion of 
EAC patients with stage I tumors, to 45.1%, 17.6% and 2.1% for patients with stage II, III and 
IV tumors, respectively.  
 
In addition, the prognosis for patients who receive surgical therapy has improved.166 Reasons for 
these improvements include earlier tumor detection due to higher general awareness and 
surveillance of individuals with BE, more accurate selection of patients for curative treatment, 
better surgical and perioperative therapy, and the addition of neoadjuvant chemotherapy or 
chemoradiotherapy for localized EAC.6,167–169  The tumor response to neoadjuvant chemotherapy 
or chemoradiotherapy is another important prognostic factor. Tumor stage at the time of surgery 
(pathological tumor stage) might be an even stronger prognostic factor than tumor stage at the 
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time of diagnosis (clinical tumor stage).170 Other prognostic factors include patients’ 
performance status, co-morbidities, and health-related quality of life.5,171  
 
Given the poor prognosis of patients with EAC, screening of certain high-risk individuals could 
be used to detect premalignant lesions (e.g. BE, dysplasia) or invasive EAC at a curable stage. 
However, endoscopic screening might not be cost-effective or feasible, so less-invasive methods 
such as Cytosponge or breath tests might be used.172,173  Screening and early detection of EAC is 
discussed in further detail in the accompanying article in this issue by di Pietro et al.174  
 
Future Directions 
We have reviewed the epidemiological studies of EAC. It is important that future research builds 
upon current evidence. Important subjects for future research include: 
• Continued evaluation of population trends in EAC incidence and prognosis, particularly 
in screening trials in high-risk population groups 
• Efforts to improve earlier detection of EAC, to improve prognosis and treatment options 
• Improved measurement of lifestyle exposures in epidemiological studies of EAC, for 
example through objective measures of physical activity and improved methods of 
dietary assessment 
• Further interventional studies of anti-reflux therapies, weight loss, physical activity, and 
smoking cessation in individuals at risk of EAC 
• Increasing our understanding of mechanisms of pathogenesis, and genetic and lifestyle 
factors than increase or decrease risk of EAC 
• Improved understanding of the male predominance for EAC and associated biological 
mechanisms 
• Identifying strategies for EAC prevention, and pharmaco-epidemiological studies to 
quantify the magnitude of associations between medications and EAC risk  
• Increasing our understanding of bacteria and the gastrointestinal microbiome in EAC 
development 
• Molecular pathology epidemiology studies to determine whether the association between 
modifiable risk factors and EAC differs with molecular subtype of tumor175 
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Molecular pathology epidemiology studies have been successfully applied to studies of other 
cancers, most notably to colorectal cancer, to increase understanding of etiology and 
progression.176–178 Such studies require collection of epidemiological data and tissue from EAC 
patients to study associations between risk factors and molecular subtypes of EAC. These, and 
the other research directions, will require strong infrastructure and input from interdisciplinary 
research teams, and collaboration among research groups and consortia.  
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Figure 1 legend: Incidence trends of esophageal adenocarcinoma in whites in the US, 1973–
2014 (A) and the trends in Sweden, 1970-2015 (B). Data sources: Surveillance, 
Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER 
9 Registries Research Data, Nov 2016 Submission; and the Swedish Cancer Registry. 
 
Figure 2 legend: Forest plots of associations between heartburn and regurgitation exposures in 
relation to case and control groups in BEACON.51 (A) The association between recurrent 
heartburn or recurrent regurgitation in relation to esophageal adenocarcinoma. (B) The 
association between heartburn and regurgitation duration in relation to esophageal 
adenocarcinoma. (C): The association between heartburn and regurgitation frequency in 
relation to esophageal adenocarcinoma. D. The frequency of recurrent heartburn or 
recurrent regurgitation exposure in case and control groups by study. For each plot, each 
white square represents the study-specific odds ratio (A–C) or prevalence of exposure (D) 
and the black diamond represents the overall estimate. The arms of each symbol portray 
the 95% confidence intervals. 
 
Figure 3 legend: Net survival by tumor stage of esophageal adenocarcinoma patients diagnosed 
in Northern Ireland, 2003-2010. Data sources: The Northern Ireland Cancer Registry. The 
total number of patients included in analysis by stage I, II, III, IV and unknown tumor 
type are 59, 95, 112, 185 and 288, respectively. 
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Table 1. Non-genetic risk factors for EAC 
Factor Direction 
of 
association 
Strength of 
association 
Type of studies 
conducted  
Related notable findings References 
Gastroesophageal 
reflux disease 
Positive 6.2-fold 
increased 
risk 
Meta-analyses of 
population-based 
studies 
The association was stronger in young adults (<50 years) 
than in older individuals. 
51-55 
Anti-reflux 
therapies 
Inverse Inconsistent Meta-analyses of 
population-based 
studies 
No association between proton-pump inhibitors use and 
EAC risk observed with adjustment for confounders; role 
of anti-reflux surgery in preventing EAC remains 
uncertain. 
54,61-65 
Obesity Positive Strong, 
linear dose-
response 
association  
Meta-analyses of 
population-based 
cohort studies 
Abdominal adiposity has been associated with increased 
EAC risk after adjustment for body mass index. 
52,70-77 
Weight loss Probably 
inverse 
Uncertain Interventions of 
obesity surgery 
Existing evidence remains insufficient. 97 
Tobacco 
smoking 
Positive 2–3-fold 
increased 
risk. 
Meta-analyses of 
population-based 
studies 
Individuals who have stopped smoking for ten years or 
more having an approximate 30-40% reduced risk of EAC 
compared with current smokers.  
115-118, 
121 
Alcohol No 
association 
No 
association 
Meta-analyses of 
population-based 
Potential inverse association for moderate consumption of 
alcohol, particularly wine.  
126-131 
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studies 
Dietary factors Various Various  Mostly case-control 
studies 
Evidence is limited for a protective effect of vegetable 
intake and dietary fiber. Insufficient for all other factors. 
125, 132-
141 
Physical activity Inverse 30%–40% 
reduced 
risk 
Cohort and case-
control studies 
Potential increased risks of EAC and sedentary behavior 
require further study.  
125, 142-
150 
Helicobacter 
pylori infection 
Inverse 40%–60% 
reduced 
risk 
Meta-analyses of 
observational studies 
Evidence for other infectious agents remains insufficient.  98-112 
Menopausal 
hormone therapy 
and oral 
contraceptives 
Inverse 25% 
reduced 
risk 
Meta-analyses of 
population-based 
studies 
Confounding by indication could not be ruled out in many 
studies. 
151, 152 
Breastfeeding Inverse 58% 
reduced 
risk 
Meta-analyses of 
population-based 
case-control studies 
Decreased EAC risk associated with increasing duration 
of breastfeeding >1 year. Other reproductive factors 
require further study.  
153 
Non-steroidal 
anti-
inflammatory 
drugs 
Inverse 32%–64% 
reduced 
risk 
Meta-analyses of 
population-based 
studies and 
Randomized 
controlled trials 
Benefits of these medications for EAC prevention need to 
be carefully considered against potential harm due to 
known side effects.  
154, 155 
Statins Inverse 41% Meta-analyses of Reduced EAC risk associated with statins use in patients 62, 156 
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reduced 
risk 
population-based 
studies 
with BE; the preventive effect of statins against EAC 
development remains to be confirmed in large 
randomized controlled trials. 
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Table 2. Dietary factors, nutrient status, and risk of reflux esophagitis, BE, and 
EAC 
Dietary variable Reflux 
esophagitis 
BE EAC Reference 
FOOD GROUPS    
Dairy products - + + Mulholland et 
al135 
Fruit and 
vegetables 
 - - Anderson et al140 
Total red meat = = = O’Doherty et al137 
White meat - - -  
Processed meat ++ + +  
Total fish + + +  
NUTRIENT INTAKES   
Total carbohydrate = = - - Mulholland et 
al136 
Glycemic index + = ++  
Glycemic load = = =  
Dietary fiber - - - -  
Vitamin D - = ++ Mulholland et 
al135 
Calcium - = =  
Magnesium - - - - - - Dai et al133 
Folate - - - - - Sharp et al134 
Vitamin B12 = ++ ++  
Vitamin B6 - - - - - -  
Vitamin C - - - - - Murphy et al141 
Vitamin E - - =  
Zinc - - +  
Copper - - =  
Selenium + = =  
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Notes: Data taken from the All Ireland Factors Influencing the Barrett’s Adenocarcinoma 
Relationship study. 
Table 2 Legend:  
- - Significant inverse (protective) associations observed.  
– Non-significant inverse (protective) associations observed.  
= No significant associations observed.  
+ Non-significant positive (increased risk) associations observed.  
++ Significant positive (increased risk) associations observed.  
Blank cells indicate that the association was not studied in that disease group 
Antioxidant index + = - -  
Heme iron  ++ ++ O’Doherty et al138 
Non-heme iron  - - - -  
Total fat ++ + ++ O’Doherty et al137 
Saturated fat ++ = ++  
Monounsaturated 
fat 
++ + ++  
Polyunsaturated fat ++ = +  
NUTRIENT STATUS   
Serum iron  -  O’Doherty et al138 
Ferritin  - -   
Toenail iron  - - -  
Toenail Selenium  - - = O’Rorke et al139 
Toenail Zinc  ++ =  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
